ArticleEJHaem2022

Long-term efficacy and safety of programmed death-1 (PD-1) antibody alone in relapsed/refractory human immunodeficiency virus-associated Hodgkin lymphoma.

Chaoyu Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.